KROS (Keros Therapeutics) Stock Based Compensation: $26.03 Mil (TTM As of Mar. 2026)


KROS Keros Therapeutics Inc KROS
30 GF Score
Price $11.59
! 2 Warning Signs
View Full Analysis

What is Keros Therapeutics Stock Based Compensation?

Keros Therapeutics KROS -0.47% 30 Stock Based Compensation is $26.03 Mil as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Keros Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $6.20 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $26.03 Mil.

Keros Therapeutics Stock Based Compensation Related Terms

Keros Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics Stock Based Compensation Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 11.72 18.68 28.76 34.87 28.70

Keros Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.86 8.54 3.99 7.31 6.20
KROS
30GF Score
Keros Therapeutics Inc KROS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.03 Mil.

What does a Stock Based Compensation of $26.03 Mil mean?
Keros Therapeutics (KROS) has a Stock Based Compensation of $26.03 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Keros Therapeutics and its competitors.
Is Keros Therapeutics' Stock Based Compensation too high?
Keros Therapeutics' current Stock Based Compensation is $26.03 Mil. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Stock Based Compensation compare to CDXS and CAMP?
Keros Therapeutics' Stock Based Compensation of $26.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Keros Therapeutics and its competitors. Keros Therapeutics's current Stock Based Compensation is $26.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current Stock Based Compensation of $26.03 Mil. The current Stock Based Compensation is $26.03 Mil. Keros Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Stock Based Compensation is $26.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score

Get the complete analysis for KROS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.59
Price